Adam Feuerstein, a senior writer and biotech columnist for STAT, has recently introduced a weekly email newsletter titled Adam’s Biotech Scorecard. This newsletter, which is exclusive to STAT+ subscribers, commenced distribution on March 28, 2026, and aims to deliver insightful analysis at the intersection of Wall Street and biotechnology.
Feuerstein brings decades of experience to the table, having extensively covered the biotech sector throughout his career. He also co-hosts STAT’s weekly podcast, ‘The Readout LOUD’. For those interested in reaching him, he can be contacted via Signal at stataf.54.
Subscribers to Adam’s Biotech Scorecard can expect:
- A comprehensive scorecard-style analysis of the biotech industry.
- Valuable insights that may challenge conventional perceptions within the sector.
- Regular updates focusing on current trends and developments in biotechnology.
For current STAT+ subscribers, Adam’s Biotech Scorecard is available free of charge. New subscribers can access this newsletter through various STAT+ plans, which cater to both individual and group needs. Those without a STAT+ subscription have the opportunity to sign up for these plans to gain access to this specialized content.
Feuerstein’s newsletter promises a distinctive perspective, enhancing subscribers’ understanding of the complexities involved in the biotechnology landscape.